The Opticyte Cell O₂ Monitor is a $3 Billion+ Global Market Opportunity

Opticyte has been capital-efficient and is funded for the next year with a non-dilutive grant. The company has issued patents, a clear De Novo pathway, and the potential to deliver significant cost savings to hospitals. Demonstrating strong momentum and credibility, Opticyte is a medical device innovator to watch.

The company is currently raising Series A. Milestones include product development, FDA clearance, and execution of a multi-center randomized controlled trial.

“I am confident that should the preliminary data be confirmed in larger studies, there will be rapid and widespread adoption of this technology in both the hospital and prehospital settings.”

Eileen M. Bulger, MD, Chief of Trauma, Harborview Medical Center, Seattle

Connect with the Opticyte Team

If you’re a qualified investor and potential partner interested in Opticyte’s preclinical stage technology please reach out through our contact form.